Literature DB >> 23574723

MicroRNA-143 inhibits tumor growth and angiogenesis and sensitizes chemosensitivity to oxaliplatin in colorectal cancers.

Xu Qian1, Jing Yu, Yu Yin, Jun He, Lin Wang, Qi Li, Lou-Qian Zhang, Chong-Yong Li, Zhu-Mei Shi, Qing Xu, Wei Li, Li-Hui Lai, Ling-Zhi Liu, Bing-Hua Jiang.   

Abstract

Colorectal cancer (CRC) is one of the leading cancer-related causes of death in the world. Recently, downregulation of microRNA-143 (miR-143) has been observed in CRC tissues. Here in this study, we found that miR-143 expression was downregulated both in CRC patients' blood samples and tumor specimens. MiR-143 expression levels were strongly correlated with clinical stages and lymph node metastasis. Furthermore, insulin-like growth factor-I receptor (IGF-IR), a known oncogene, was a novel direct target of miR-143, whose expression levels were inversely correlated with miR-143 expression in human CRC specimens. Overexpression of miR-143 inhibited cell proliferation, migration, tumor growth and angiogenesis and increased chemosensitivity to oxaliplatin treatment in an IGF-IR-dependent manner. Taken together, these results revealed that miR-143 levels in human blood and tumor tissues are associated with CRC cancer occurrence, metastasis and drug resistance, and miR-143 levels may be used as a new diagnostic marker and therapeutic target for CRC in the future.

Entities:  

Keywords:  IGF-IR; angiogenesis; chemotherapy; microRNA-143; tumorigenesis

Mesh:

Substances:

Year:  2013        PMID: 23574723      PMCID: PMC3674066          DOI: 10.4161/cc.24477

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  51 in total

1.  Curcumin targets FOLFOX-surviving colon cancer cells via inhibition of EGFRs and IGF-1R.

Authors:  Bhaumik B Patel; Deepshika Gupta; Althea A Elliott; Vivek Sengupta; Yingjie Yu; Adhip P N Majumdar
Journal:  Anticancer Res       Date:  2010-02       Impact factor: 2.480

2.  Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR).

Authors:  Evan M Kroh; Rachael K Parkin; Patrick S Mitchell; Muneesh Tewari
Journal:  Methods       Date:  2010-02-08       Impact factor: 3.608

3.  Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer.

Authors:  Zhibin Hu; Xi Chen; Yang Zhao; Tian Tian; Guangfu Jin; Yongqian Shu; Yijiang Chen; Lin Xu; Ke Zen; Chenyu Zhang; Hongbing Shen
Journal:  J Clin Oncol       Date:  2010-03-01       Impact factor: 44.544

4.  Circulating micro-RNA expression profiles in early stage nonsmall cell lung cancer.

Authors:  Niels H H Heegaard; Aaron J Schetter; Judith A Welsh; Mitsuhiro Yoneda; Elise D Bowman; Curtis C Harris
Journal:  Int J Cancer       Date:  2011-08-26       Impact factor: 7.396

Review 5.  Colorectal cancer.

Authors:  David Cunningham; Wendy Atkin; Heinz-Josef Lenz; Henry T Lynch; Bruce Minsky; Bernard Nordlinger; Naureen Starling
Journal:  Lancet       Date:  2010-03-20       Impact factor: 79.321

6.  Loss of brain-enriched miR-124 microRNA enhances stem-like traits and invasiveness of glioma cells.

Authors:  Hongping Xia; William K C Cheung; Samuel S Ng; Xiaochun Jiang; Songshan Jiang; Johnny Sze; Gilberto K K Leung; Gang Lu; Danny T M Chan; Xiu-Wu Bian; Hsiang-fu Kung; Wai Sang Poon; Marie C Lin
Journal:  J Biol Chem       Date:  2012-01-17       Impact factor: 5.157

7.  Effect of silencing PARG in human colon carcinoma LoVo cells on the ability of HUVEC migration and proliferation.

Authors:  J Pan; N J S Fauzee; Y-l Wang; Y-T Sheng; Y Tang; J-Q Wang; W-q Wu; J-x Yan; J Xu
Journal:  Cancer Gene Ther       Date:  2012-08-24       Impact factor: 5.987

8.  Validation of the type 1 insulin-like growth factor receptor as a therapeutic target in renal cancer.

Authors:  John S P Yuen; Erdem Akkaya; Yong Wang; Megumi Takiguchi; Sandra Peak; Mark Sullivan; Andrew S Protheroe; Valentine M Macaulay
Journal:  Mol Cancer Ther       Date:  2009-06-09       Impact factor: 6.261

9.  Diagnostic microRNA markers to screen for sporadic human colon cancer in blood.

Authors:  Farid E Ahmed; Nancy C Amed; Paul W Vos; Chris Bonnerup; James N Atkins; Michelle Casey; Gerard J Nuovo; Wade Naziri; John E Wiley; Ron R Allison
Journal:  Cancer Genomics Proteomics       Date:  2012 Jul-Aug       Impact factor: 4.069

10.  MiR-128 inhibits tumor growth and angiogenesis by targeting p70S6K1.

Authors:  Zhu-mei Shi; Jing Wang; Zhiping Yan; Yong-ping You; Chong-yong Li; Xu Qian; Yu Yin; Peng Zhao; Ying-ying Wang; Xie-feng Wang; Ming-na Li; Ling-Zhi Liu; Ning Liu; Bing-Hua Jiang
Journal:  PLoS One       Date:  2012-03-19       Impact factor: 3.240

View more
  68 in total

Review 1.  MicroRNAs in colorectal cancer as markers and targets: Recent advances.

Authors:  Jing-Jia Ye; Jiang Cao
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

2.  Tumor suppressor role of miR-133a in gastric cancer by repressing IGF1R.

Authors:  Yu Gong; Jun Ren; Kun Liu; Li-Ming Tang
Journal:  World J Gastroenterol       Date:  2015-03-14       Impact factor: 5.742

Review 3.  MicroRNAs are important regulators of drug resistance in colorectal cancer.

Authors:  Yang Zhang; Jing Wang
Journal:  Biol Chem       Date:  2017-07-26       Impact factor: 3.915

4.  miR-423-5p contributes to a malignant phenotype and temozolomide chemoresistance in glioblastomas.

Authors:  Shouwei Li; Ailiang Zeng; Qi Hu; Wei Yan; Yanwei Liu; Yongping You
Journal:  Neuro Oncol       Date:  2016-07-28       Impact factor: 12.300

5.  Function of insulin-like growth factor 1 receptor in cancer resistance to chemotherapy.

Authors:  Jingsheng Yuan; Zhijie Yin; Kaixiong Tao; Guobing Wang; Jinbo Gao
Journal:  Oncol Lett       Date:  2017-10-26       Impact factor: 2.967

Review 6.  An update on miRNAs as biological and clinical determinants in colorectal cancer: a bench-to-bedside approach.

Authors:  Wenhao Weng; Junlan Feng; Huanlong Qin; Yanlei Ma; Ajay Goel
Journal:  Future Oncol       Date:  2015       Impact factor: 3.404

7.  MicroRNA-1301 inhibits proliferation of human glioma cells by directly targeting N-Ras.

Authors:  Tongle Zhi; Kuan Jiang; Chuanzhuo Zhang; Xiupeng Xu; Weining Wu; Er Nie; Tianfu Yu; Xu Zhou; Zhongyuan Bao; Xin Jin; Junxia Zhang; Yingyi Wang; Ning Liu
Journal:  Am J Cancer Res       Date:  2017-04-01       Impact factor: 6.166

8.  MicroRNA-520d-5p inhibits human glioma cell proliferation and induces cell cycle arrest by directly targeting PTTG1.

Authors:  Tongle Zhi; Kuan Jiang; Xiupeng Xu; Tianfu Yu; Weining Wu; Er Nie; Xu Zhou; Xin Jin; Junxia Zhang; Yingyi Wang; Ning Liu
Journal:  Am J Transl Res       Date:  2017-11-15       Impact factor: 4.060

Review 9.  Epigenetic Alterations in Colorectal Cancer: Emerging Biomarkers.

Authors:  Yoshinaga Okugawa; William M Grady; Ajay Goel
Journal:  Gastroenterology       Date:  2015-07-26       Impact factor: 22.682

10.  MiR-195 inhibits the growth and metastasis of NSCLC cells by targeting IGF1R.

Authors:  Xiaoli Wang; Yuchang Wang; Hongwen Lan; Jun Li
Journal:  Tumour Biol       Date:  2014-05-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.